High importanceMet
Seasonal vaccine sales
ExpectedVaccine-driven total revenue of $890.25 millionanalysts' consensus
The resultTotal revenue of $1.31 billion
Vaccine sales are Moderna’s main source of revenue and help fund its research.
Moderna D
D
MRNA
246.700
USD
-5.07
(-2.02%)
Pre Open·252.480USD+5.780(+2.34%)
Last updated: · Delayed 15 min
Moderna earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Moderna reports its Q4 FY2026 results on 12 February 2027, before the market opens. Analysts expect earnings per share of -2.01 USD and revenue of 556.40M USD.
In Q3 FY2026, reported on 6 November 2026, Moderna earned 0.38 USD a share against the -1.10 USD analysts expected (+134.5%), on revenue of 1.31B USD against 890.25M USD (+47.5%).
- Last EPS surpriseWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +134.5%
- Last revenue surprise
- +47.5%
- Move after the last reportWhat is the next-day move after earnings? The next-day move is how much a stock's price changed on the first trading day after an earnings report: how the market took the results.
- +5.4%
- Average move after earningsWhat is the next-day move after earnings? The next-day move is how much a stock's price changed on the first trading day after an earnings report: how the market took the results.
- 6.8%
EPS and revenue against estimates
Next earnings · Q4 FY2026
EPS estimate
-2.01 USD
Revenue estimate
556.40M USD
Last quarter · Q3 FY2026
EPS0.38Beat +134.5%Revenue1.31BBeat +47.5%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth | Next-day move |
|---|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | -1.72 | — | — | — | 264.28M | — | — | -32.06% | — | |
| Q4 FY2026 | -2.01 | — | — | — | 556.40M | — | — | -17.94% | — | |
| Q3 FY2026 | -1.10 | 0.38 | +134.55% | — | 890.25M | 1.31B | +47.49% | +29.23% | +5.4% | |
| Q2 FY2026 | -2.03 | -1.97 | +2.96% | — | 102.93M | 145.00M | +40.87% | +2.11% | -5.5% | |
| Q1 FY2026 | -4.45 | -3.40 | +23.60% | — | 236.36M | 389.00M | +64.58% | +263.55% | -1.2% | |
| Q4 FY2025 | -2.54 | -2.11 | +16.93% | — | 635.15M | 678.00M | +6.75% | -29.08% | +5.3% | |
| Q3 FY2025 | -1.87 | -0.51 | +72.73% | -1,800.00% | 920.86M | 1.02B | +10.33% | -45.23% | +3.4% | |
| Q2 FY2025 | -2.99 | -2.13 | +28.76% | — | 893.29M | 142.00M | -84.10% | -41.08% | -6.7% | |
| Q1 FY2025 | -2.92 | -2.52 | +13.70% | — | 116.75M | 107.00M | -8.35% | -35.93% | -5.4% | |
| Q4 FY2024 | -2.68 | -2.50 | +6.72% | -554.55% | 942.82M | 956.00M | +1.40% | -66.01% | +3.3% | |
| Q3 FY2024 | -1.91 | 0.03 | +101.57% | — | 1.25B | 1.86B | +48.39% | +1.31% | -2.9% | |
| Q2 FY2024 | -3.35 | -3.33 | +0.60% | — | 128.41M | 241.00M | +87.68% | -29.94% | -21.0% | |
| Q1 FY2024 | -3.56 | -3.07 | +13.76% | -1,715.79% | 93.26M | 167.00M | +79.07% | -90.91% | +12.6% | |
| Q4 FY2023 | -0.97 | 0.55 | +156.70% | -84.76% | 2.51B | 2.81B | +12.02% | -44.67% | +13.5% | |
| Q3 FY2023 | -1.93 | -9.53 | -393.19% | -476.68% | 1.38B | 1.83B | +32.25% | -43.14% | -6.6% | |
| Q2 FY2023 | -3.84 | -3.62 | +5.73% | -169.08% | 319.64M | 344.00M | +7.62% | -92.47% | -0.2% | |
| Q1 FY2023 | -1.77 | 0.19 | +110.73% | -97.79% | 1.18B | 1.84B | +56.01% | -69.06% | +3.3% | |
| Q4 FY2022 | 4.68 | 3.61 | -22.86% | -68.02% | 5.02B | 5.08B | +1.33% | -26.84% | -6.7% | |
| Q3 FY2022 | 3.29 | 2.53 | -23.10% | -67.14% | 3.53B | 3.22B | -8.69% | -33.32% | -0.7% | |
| Q2 FY2022 | 4.55 | 5.24 | +15.16% | -18.89% | 4.10B | 4.57B | +11.45% | +8.33% | +15.9% | |
| Q1 FY2022 | 5.21 | 8.58 | +64.68% | +202.11% | 4.20B | 5.94B | +41.30% | +240.79% | +5.9% | |
| Q4 FY2021 | 9.90 | 11.29 | +14.04% | — | 6.80B | 6.95B | +2.23% | +2,929.54% | +15.0% | |
| Q3 FY2021 | 9.05 | 7.70 | -14.92% | — | 6.45B | 4.83B | -25.09% | +39,430.12% | -17.9% | |
| Q2 FY2021 | 5.96 | 6.46 | +8.39% | — | 4.21B | 4.22B | +0.18% | +14,719.63% | -0.6% | |
| Q1 FY2021 | 2.39 | 2.84 | +18.83% | — | 2.41B | 1.74B | -27.80% | +39,007.02% | -1.4% | |
| Q4 FY2020 | -0.25 | -0.69 | -176.00% | — | 459.72M | 229.38M | -50.11% | +2,073.55% | +2.0% | |
| Q3 FY2020 | -0.43 | -0.59 | -37.21% | — | 115.09M | 12.22M | -89.39% | -8.41% | +8.4% | |
| Q2 FY2020 | -0.36 | -0.31 | +13.89% | — | 74.91M | 28.44M | -62.03% | +183.57% | -3.5% | |
| Q1 FY2020 | -0.37 | -0.35 | +5.41% | — | 8.39M | 4.46M | -46.87% | -68.42% | +8.5% | |
| Q4 FY2019 | -0.43 | -0.37 | +13.95% | — | 15.95M | 10.55M | -33.85% | -67.84% | +21.5% | |
| Q3 FY2019 | -0.43 | -0.37 | +13.95% | — | 19.81M | 13.34M | -32.67% | -68.06% | -4.6% | |
| Q2 FY2019 | -0.42 | -0.41 | +2.38% | — | 14.04M | 10.03M | -28.56% | — | +5.0% | |
| Q1 FY2019 | -0.35 | -0.40 | -14.29% | — | 14.42M | 14.12M | -2.13% | — | -1.0% | |
| Q4 FY2018 | -0.36 | -1.78 | -394.44% | — | — | 32.82M | — | — | -3.6% | |
| Q3 FY2018 | — | -0.27 | — | — | — | 41.76M | — | — | — |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | -2.85 | — | — | — | 3.38B | — | — | +38.79% |
| FY2027 | -4.76 | — | — | — | 2.43B | — | — | +15.86% |
| FY2026 | -8.42 | — | — | — | 2.10B | — | — | +8.13% |
| FY2025 | -7.84 | -7.27 | +7.24% | — | 1.91B | 1.94B | +1.83% | -39.64% |
| FY2024 | -9.05 | -8.87 | +1.99% | — | 3.21B | 3.22B | +0.33% | -52.84% |
| FY2023 | -13.46 | -12.41 | +7.78% | -162.17% | 6.47B | 6.83B | +5.58% | -63.71% |
| FY2022 | 21.26 | 19.96 | -6.10% | -29.45% | 19.13B | 18.81B | -1.67% | +6.06% |
The move is the shares' change on the trading day after the report: after a report after the close, the next day's close on the report day's; before the open, the report day's close on the day before's. Surprise is the reported figure against the analysts' average estimate.
Q3 FY2026
What the market waited for, and what cameWhat is the market waiting for in a report? The two to four figures investors watch most in a company's next earnings report, each with the number analysts or the company expect, and after the report, whether it came in.
From the last earnings call, the company's guidance and analysts' previews, and checked against the report when it comes.
High importanceNot in the report
Full-year revenue outlook
ExpectedFull-year revenue guidance of about $2.10 billionanalysts' consensus
The resultNot in the report
The outlook will show how much sales Moderna expects from the rest of the vaccination season.
High importanceMet
Operating expense outlook
ExpectedFull-year operating expenses of about $4.7 billioncompany guidance
The resultFull-year operating expenses of $4.5 billion, excluding the litigation charge
Keeping expenses in check could reduce losses and preserve cash for research.
Medium importanceMet
Cash balance outlook
ExpectedYear-end cash and investments of $4.7 billion to $5.2 billioncompany guidance
The resultYear-end cash and investments guidance of $8.1 billion to $8.3 billion
A stronger cash balance would give Moderna more room to fund its research without raising money.
Beat recordWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 47.7% off the result, either way, and their revenue estimate 40.9%, over the last 12 quarters.
- EPS beats
- 24 / 32
- Revenue beats
- 18 / 31
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +47.7%
- Since
- March 2019
See also:Forecast,EPS,Income statement
Common questions about Moderna's earnings
Source: Financial Modeling Prep